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Abstract
Background: To report about initial clinical experience in radiation treatment of carcinoma of prostate with volumetric 
modulated arcs with the RapidArc (RA) technology.
Methods: Forty-five patients with a median age of 72 ± 3, affected by prostate carcinoma (T1c: 22 patients, T2a-b: 17 
patients, T3a-b: 6 patients. N0: 43 patients, N1-Nx: 2 patients, all M0), with initial PSA of 10.0 ± 3.0 ng/mL, were treated 
with RapidArc in a feasibility study. All patients were treated with single arc using 6MV photons. Dose prescription 
ranged between 76 (7 patients) and 78 Gy (38 patients) in 2Gy/fraction. Plan quality was assessed by means of Dose 
Volume Histogram (DVH) analysis. Technical parameters of arcs and pre-treatment quality assurance results (Gamma 
Agreement Index, GAI) are reported to describe delivery features. Early toxicity was scored (according to the Common 
Terminology Criteria of Adverse Effects scale, CTCAE, scale) at the end of treatment together with biochemical 
outcome (PSA).
Results: From DVH data, target coverage was fulfilling planning objectives: V95% was in average higher than 98% and 
V107%~0.0% (D2%~104.0% in average). Homogeneity D5%-D95% ranged between 6.2 ± 1.0% to 6.7 ± 1.3%. For rectum, all 
planning objectives were largely met (e.g. V70Gy = 10.7 ± 5.5% against an objective of < 25%) similarly for bladder (e.g. 
D2% = 79.4 ± 1.2Gy against an objective of 80.0Gy). Maximum dose to femurs was D2% = 36.7 ± 5.4Gy against an 
objective of 47Gy. Monitor Units resulted: MU/Gy = 239 ± 37. Average beam on time was 1.24 ± 0.0 minutes. Pre-
treatment GAI resulted in 98.1 ± 1.1%. Clinical data were recorded as PSA at 6 weeks after RT, with median values of 0.4 
± 0.4 ng/mL. Concerning acute toxicity, no patient showed grade 2-3 rectal toxicity; 5/42 (12%) patients experienced 
grade 2 dysuria; 18/41 (44%) patients preserved complete or partial erectile function.
Conclusion: RapidArc proved to be a safe, qualitative and advantageous treatment modality for prostate cancer.
Background
In Switzerland an increasing incidence of prostate adeno-
carcinoma was observed in the last 10 years, with 5668
new cases/year, attaining to the 29.6% of all male malig-
nancies in 2006, and an yearly average mortality of 1292
patients between 2003 and 2006 over a population of
about 7.4 million inhabitants [1]. In our region (of about
320'000 inhabitants) the incidence of prostate adenocar-
cinoma is also increasing with average 170 new cases/
year between 1996 and 2007 (mortality 47 patients/year,
between 1996 and 2005). A large portion of those patients
are treated by radiotherapy.
A proper planning policy, which allows to spare the
healthy tissue and at the same time ensure high cure rate,
is of particular importance due to the rate of curability of
this tumour and long survival of the patients. In this
respect new, highly conformal treatments have been
tested in the last years.
Volumetric Modulated Arc Therapy (VMAT), based on
the original investigation of K. Otto [2] has been recently
introduced in clinical practice in several institutes after
an intensive validation at planning level, compared to
IMRT or other approaches. RapidArc (RA), the Varian
solution of VMAT, is implemented as the Progressive
Resolution Optimisation (PRO) algorithm in the Eclipse
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California, USA). The optimisation process is based on an
iterative inverse planning process aiming to simultane-
ously optimise the instantaneous multi leaf collimator
(MLC) positions, the dose rate, and the gantry rotation
speed to achieve the desired dose distribution.
Pre-clinical validation of RapidArc was addressed in a
series of studies including brain tumours, head and neck,
anal canal, cervix uteri cancer and other indications [3-9].
The potential role of RA in the treatment of prostate can-
cer has been investigated by the Danish group of Rigs
Hospitalet [6], by the Vancouver group lead by K. Otto
[10,11], by the group of Duke University [12] and by the
group of Memorial Sloan Kettering [13].
At our institute, until end of January 2010, more than
250 patients have been treated with RapidArc for a vari-
ety of indications. Among these, 117 received RapidArc
treatment as part of their multidisciplinary management
of prostate adenocarcinoma.
Of these, forty-five, irradiated without inclusion of the
pelvic nodes, were included in the present study based on
the risk class. After a short transition time in the first
weeks, all prostate patients are currently treated with
RapidArc at our institute.
Aim of the present study is to report the technical and
dosimetric aspects of the treatments as well as to summa-
rize the acute toxicity findings.
Further investigations will aim to look at the long term
clinical outcome and late toxicity in relation to dosimetric
improvements in sparing of the organs at risk.
Methods
Forty-five patients were treated with RapidArc (RA) from
October 2008 to September 2009. Characteristics of
patients are summarized in table 1. Most frequent stages
were T1c and T2a-c (87% in total), N0 (96%) and all the
patients were M0. Most of patients were non operated
(96%) and the majority of them received hormonal ther-
apy (69%). Gleason score was 6-7 in all cases. Median age
was 72 years (range: 57-81 years).
The issue of target definition is highly debated for pros-
tate cancer, particularly the inclusion of the seminal vesi-
cles [14-18]. According to Kestin et al. [14] only 1% of low
risk patients with PSA < 10 ng/mL or Gleason score < 6
and clinical stage ≤T2A, demonstrated seminal vesicles
involvement. In their study, authors suggested to include
only the proximal 2-2.5 cm of the vesicles for higher
stages. Given the patient population of our study, this last
strategy for clinical target volume definition was assumed
as standard. Clinical Target Volume (CTV) was therefore
defined as the prostate plus the basis of the seminal vesi-
cles. Planning Target Volume (PTV) was the CTV with a
margin of 1 cm in all directions except posteriorly where
the margin was reduced to 0.5 cm. Some individualized
reduction toward the rectum was applied whenever the
rectum involvement was judged too high by the radiation
oncologist.
Patients were divided into two groups: Group A (16
patients) received a total dose of 70Gy to a planning tar-
get volume (PTVII) including also the base of the seminal
vesicles, plus a boost of 6-8 Gy to the prostate only
(PTVI). Group B (29 patients, including two post opera-
tive patients) received a single course of treatment up to
78Gy to the entire PTV including prostate and base of
seminal vesicles (or prostatic bed for patients who
received surgery). In all cases, dose normalization was set
to mean dose to PTV. In the framework of the initial
phase of RapidArc clinical practice, no hypo-fraction-
ation or dose escalation scheme was introduced and will
be part of future investigations.
Table 1: Summary of patients characteristics at treatment start.




Stage T T1c 22 (49%)
T2a-c 17 (38%)
T3a-b 6 (13%)
Stage N N0 43 (96%)
N1 1 (2%)
Nx 1 (2%)
Stage M M0 45 (100%)
M1 0 (0%)
Gleason score 6 25 (56%)
7 20 (44%)
PSA at staging (μg/l)
(Median and range)
10.0 [4.7, 33.8]
Hormonotherapy Yes 31 (69%)
No 14 (31%)
Surgery Yes 2 (4%)
No 43 (96%)
Dose Prescription:
Group A 70+6 Gy 7 (16%)
70+8 Gy 9 (20%)
Group B 78 Gy 29 (64%)
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rectum, bladder, femoral heads and penile bulb. Rectum
was delineated from 1 cm above anus to the sigma tract.
In addition, as practice for all intensity modulated
patients, the Healthy Tissue (HT) was defined as the
patient's volume included in the CT dataset minus the
PTV volume. No specific immobilisation systems were
applied to prostate patients as well as no strong require-
ments on patient preparation. In this respect, patients
were asked to empty bladder about half an hour prior to
treatment and to regularize rectal evacuation during the
first two weeks of treatment, also using small glycerine
based enema one hour before treatment. Routine institu-
tional image-based patient position verification protocols
foresee 2D-2 D matching of orthogonal kV-MV images
acquired with the On Board Imaging system installed at
the accelerator with evaluation performed by radiogra-
phers and application of couch shifts if total vector length
of displacement is smaller than 7 mm. Cone Beam CT is
becoming part of our routine protocol and is now per-
formed once a week in addition to the 2D-2 D matching
(kV-MV) most common procedure. The introduction of
RapidArc and a more systematic application of image-
based patient position verification did not lead, in this
first phase of clinical practice to any modification in tar-
get or margin definitions which were kept, for this group
of patient, the same as for the previously adopted 3 D
conformal technique.
RA plans were optimised for single arcs (rotation of
358°, from 179° to 181° CCW) for a Clinac 2100iX
equipped with a Millennium-120 MLC (120 leaves with a
resolution at isocentre of 5 mm for the inner 20 cm and
10 mm for the outer 2 × 10 cm) and a photon beam
energy of 6MV. Further details on RA technique can be
found in [4,5]. Plan optimisation was performed reinforc-
ing, with appropriate dose volume constraints depending
on the individual patient and not reported here, the
achievement of the following planning objectives. For
PTV plans were optimised aiming to obtain: V95% > 98%
and V107% = 0.0%. Concerning bladder the aim was to
keep mean dose < 45Gy and D2% < 80Gy. Planning objec-
tives for rectum were: mean < 45Gy, V50Gy < 50%, V60Gy <
40%, V70Gy < 15%. For femoral heads, dose objective was
D2% < 47Gy. The dose of 30Gy was considered as objec-
tive for mean dose to penile bulb. No explicit planning
objectives were set for healthy tissue.
All dose distributions were computed with the Aniso-
tropic Analytical Algorithm (AAA) implemented in the
Eclipse planning system with a calculation grid resolution
of 2.5 mm.
Technical features of treatments have been reported in
terms of main delivery parameters (field and control
point (CP) size, MU, MU/deg and MU/Gy, Dose Rate
(DR), Gantry Speed (GS), Collimator angle, beam-on
time). Results of pre-treatment plan quality assurance are
reported as Gamma Agreement Index (GAI), i.e. the per-
centage of modulated field area passing the γ-index crite-
ria of Low [19] with thresholds on dose difference set to
ΔD = 3% of the significant maximum dose, and on Dis-
tance to Agreement set to DTA = 3 mm. Measurements
and analysis were performed by means of the GLAaS
methodology described in [20,21] based on absorbed
dose to water from EPID measurements.
Dosimetric quality of treatments was measured from
the dose volume histogram (DVH) analysis. For PTV the
following data were reported: PTV coverage (D2%, D98%,
V95%, V107%), homogeneity (D5%-D95%) and conformity
(CI90%). CI90% is defined as the ratio between the volume
of patient irradiated at 90% of the prescribed dose and the
PTV volume. For OARs, the mean dose, the maximum
dose (D2%) and appropriate values of VxGy (volume receiv-
ing at least × Gy) were scored. For Healthy Tissue, the
integral dose DoseInt was reported as well. This is mea-
sured as the integral of the dose delivered to the entire
HT and is expressed in Gy cm3.
Clinical outcome of treatments was recorded in terms
of observed global acute toxicity, particularly dysuria,
rectal toxicity and preservation of erectile function (in
non operated patients). Toxicity scoring was assessed by
non blind radiation oncologists in charge of the various
patients and according to the National Cancer Institute
Common Terminology Criteria of Adverse Effects scale
(CTCAE version 3 [22]) as part of the routine visits dur-
ing treatment and follow up protocols. Biochemical out-
come was measured in terms of PSA reporting its value at
treatment start and at end (6 weeks after RT) of radiation
therapy course.
Results
Figure 1 shows examples of dose distributions for one
patient in axial, coronal and sagittal planes. Colourwash
is in the interval from 30 to 81Gy. Figure 2 reports the
average DVHs (computed from all the 45 patients) for
CTV, PTV, organs at risk and healthy tissue. Dashed lines
represent the inter-patient variability at one standard
deviation.
Table 2 summarises the technical features of the treat-
ment characteristics. Table 3 and Table 4 report results of
the DVH analysis. Table 5 records the clinical outcome of
the treatments as early acute reactions and PSA values.
From the summary of main technical features it derives
that treatment of prostate is characterised by relatively
small field and control point areas resulting in a low out-
put factor requiring high number of MU per minute and
high average dose rate. With conventional fractionation
Pesce et al. Radiation Oncology 2010, 5:54
http://www.ro-journal.com/content/5/1/54
Page 4 of 8and single arcs, gantry speed is kept constant at maxi-
mum speed.
Pre-treatment quality assurances of RA plans resulted
in an average gamma agreement index GAI 3% superior
to the acceptance threshold of 95% set as reference in our
institute.
Dosimetric data showed that all planning objectives
were met for PTVI and PTVII-PTVI (for group A only).
Conformity of treatment, not explicitly considered as a
planning objective, resulted acceptable. DVH analysis of
organs at risk showed that all planning objectives were
largely met when considering the fraction of organs not
overlapping with PTV and when considering the entire
organs (bladder and rectum) too.
Clinical data summarized in table 5 refer to acute and
early results only scored at the end of treatment. All treat-
ments were completed without unscheduled interrup-
tions related to patients. Biochemical index PSA
decreased to values close to zero at end of treatment (val-
ues are reported as median ± MAD (Median Absolute
Deviation) and range). No severe (G2/3) acute rectal tox-
icity of any type was observed while 12% of patients expe-
rienced G2 dysuria (no events with higher grade). Erectile
function was preserved in 44% of the patients.
Discussion
Based on the results of an intensive program of pre-clini-
cal investigations performed at planning level [3-9] to
assess its reliability and potential benefit, RapidArc (a
Volumetric Modulated Arc Therapy implemented on
Varian linear accelerators and planning systems) was
introduced in clinical practice of our institute since Sep-
tember 2008 for a variety of indications. The present
study reports about the early findings from the treatment
of a group of 45 patients affected by prostate carcinoma.
The main objective of this first phase of clinical intro-
duction of RA is the assessment of the possibility to
administer to patients standard radiotherapy treatments
and moreover to investigate the potentials of improve-
ments. These results were easily achieved in this group of
patients: rectum tolerance, derived from [4,23] were
respected with a reduction of a factor about 2 or more of
the volume irradiated at medium-high doses in the range
of 50-70 Gy and a mean reduction of about 5Gy for the
mean dose. Tolerance on mean bladder dose, derived
from [3], was in average met with a quite large inter-
patient variability (seen also in the volume of the bladder
itself ) due to the absence of a strict bladder filling proto-
col in our institute. Penile bulb involvement resulted
compatible with objectives enforced in other investiga-
tions [24].
The dosimetric results reported here might also sup-
port the activation of a second clinical phase, aiming to
implement more aggressive fractionation schemes (either
with hypo-fractionation or dose escalation approaches,
and eventually including simultaneous integrated boost
modalities to discriminate between prostate and seminal
vesicles).
Having achieved the aimed quality of treatments, inves-
tigations of technical features of delivered plans, in com-
parison with previously reported data for different groups
of patients [25], allow some general consideration.
Data reported in table 5 might be compared with the
corresponding values from the pre-operative treatment of
rectal patients reported in [25]. For prostate, the small
volume and the relatively low modulation needed to fulfil
the planning objectives, lead to an approximately three-
fold smaller mean field area and about five-fold smaller
average CP area. As a consequence the MU/Gy and aver-
age DR resulted significantly higher than in the case of
rectum. These observations suggest that VMAT, in its
RapidArc form, has an inherent site-specificity of the
delivery parameters but that this is fully compensated by
the flexibility of the optimisation engine to adapt to vari-
Figure 1 Isodose distributions for one example patient for RA 
treatments for an axial plane, sagittal and coronal views. Doses 
are shown in colorwash within the interval from 30 to 81 Gy.
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Figure 2 Average Dose Volume Histograms for CTV, PTV, Bladder, Rectum, Femurs, Penile Bulb and Healthy Tissue for RA plans. Dashed 
lines represent inter-patient variability at 1 standard deviation
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free parameters (MLC and dose rate). Additional free-
dom would derive from gantry speed modulation in case
of hypo-fractionation. Quality assurance measurements
provided a confirmation of the robustness of the method
and of the independence of treatment quality from the
technical features. In fact, pre-treatment QA measure-
ments lead to a gamma agreement index identical to what
observed in the case of patients treated for rectal cancer
[25]. This suggests also an invariance of quality between
dose calculation and delivery for RapidArc treatments
from crucial delivery parameters as average dose rate,
field size, CP aperture and machine output (MU/Gy),
despite their dependence from treatment site.
Concerning clinical workflow, delivery of about 1700
RA fractions to prostate, confirmed the significant reduc-
tion of effective treatment time anticipated in the preclin-
ical phase [3-9]. For all patients and fractions, 1.24
minutes of beam on time were needed to deliver a single
fraction with the exclusion of time needed to position the
patients and to acquire data for image guidance. This
shall be incremented by the time needed to perform
image based patient position verification (depending
from day to day and modality of imaging adopted). In
total, with the procedures enforced in our institute, the
average time needed to perform image based patient
positioning, including evaluation and couch shifts is less
than 4 minutes allowing a total time shorter than 10 min-
utes for a complete session.
The smoother process of RA could decrease the dura-
tion of the treatment reducing the risk of intra-fractional
internal organ motion. In fact, bladder or rectum defor-
mation was reported by several investigations. As an
example, [26,27] using real time methods and electro-
magnetic tracking, showed a significant increase of pros-
tate displacement with increasing treatment time (one
eighth of patients showed displacements larger than 3
mm after 5 minutes from initial alignment increasing to
one quarter after 10 minutes). According to these data
and to treatment time recorded with RapidArc, it should
therefore be possible to keep average displacements of
prostate gland from position detected with pre-treatment
imaging within acceptable levels (within 3 mm), allowing
Table 2: Technical characteristics of RapidArc plans
RA
Number of arcs 1
Arc length [°] 358 ± 0.0
Beam energy 6 MV (45/45)
Beam on time [min] 1.24 ± 0.0
MU 477 ± 73
MU/Gy 239 ± 37
MU/deg 1.3 ± 0.2
Average Dose Rate [MU/min] 383 ± 55
Gantry speed [deg/sec] 4.8 ± 0.0
Collimator angle [°] 24 ± 9
Mean CP area [cm2] 29 ± 6
Mean field area [cm2] 121 ± 25
GAI [%] 98.1 ± 1.1
MU: monitor units, CP: control point
Table 3: Summary of DVH analysis for CTVs and PTVs.
Parameter Objectives Group A Group B
CTV
Volume [cm3] - 62.0 ± 25.6 67.0 ± 29.6
Mean dose [%] 99.5 ± 1.1 99.3 ± 0.5
D2% [%]
Minimise 102.9 ± 0.8 102.6 ± 1.0
D98% [%]
Maximise 96.3 ± 2.0 96.4 ± 0.5
V95% [%]
100% 97.1 ± 10.3 99.9 ± 0.2
V107% [%]
- 0.0 ± 0.0 0.0 ± 0.1
D5%-D95% [%] Minimise 5.4 ± 1.7 5.1 ± 0.9
PTVI (76-78 Gy)
Volume [cm3] - 185.4 ± 68.2 245.0 ± 64.7
Mean dose[%] 100.0% 100.0 ± 0.0 100.0 ± 0.0
D2% [%]
Minimise 103.9 ± 0.9 104.1 ± 0.6
D98% [%]
> 95% 95.9 ± 0.8 95.4 ± 1.3
V95% [%]
> 98% 98.9 ± 0.9 98.2 ± 1.7
V107% [%]
0% 0.0 ± 0.1 0.1 ± 0.1
D5%-D95% [%] Minimise 6.2 ± 1.0 6.7 ± 1.3
CI90%
1 1.3 ± 0.4 1.2 ± 0.1
PTVII- PTVI (70Gy)
Volume [cm3] - 47.5 ± 41.7 -
Mean dose [%] - 101.3 ± 0.4 -
D2% [%]
Minimise 113.0 ± 1.4 -
D98% [%]
> 95% 96.9 ± 2.7 -
V95% [%]
> 98% 98.7 ± 1.3 -
D5%-D95% [%] Minimise 12.7 ± 2.4 -
CI90%
1 1.4 ± 0.1 -
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to eventually reduce CTV to PTV margins.
It is obvious that the present study cannot be consid-
ered as conclusive and that long term observation of
patients is needed to measure outcome and late toxicity.
These preliminary results are anyway encouraging fur-
ther experience in this field.
Conclusions
Forty-five patients with prostate carcinoma were treated
with Volumetric Modulated Arc Therapy according to
the RapidArc implementation in a clinical feasibility pro-
tocol. Quality of treatments resulted in an improvement
of all planning objectives with regard to both target cov-
erage and organs at risk sparing. Clinical outcome for
early acute toxicity and assessment of biochemical out-
come showed encouraging results. Future investigations
will aim to appraise treatment of patients with inclusion
of pelvic nodes and altered fractionation schemes. Long
term outcome has to be evaluated with proper follow-up
but the first phase achieved the primary goal to demon-
strate safety and efficacy of RapidArc.
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Table 4: Summary of DVH analysis for Rectum, Bladder, Femurs, 
Penile Bulb and Healhty Tissue.
Parameter Objectives All patients All Patients
Rectum Rectum-PTV
Volume [cm3] - 58.4 ± 17.9 53.6 ± 16.2
Mean dose [Gy] < 45Gy 40.3 ± 4.2 36.7 ± 3.4
V50Gy [%]
< 60% 31.6 ± 7.6 24.7 ± 5.7
V60Gy [%]
< 45% 20.1 ± 6.6 12.1 ± 3.1
V70Gy [%]
< 25% 10.7 ± 5.5 2.4 ± 1.7
NTCP [%] < 5% 2.7 ± 1.6 1.0 ± 0.4
Bladder Bladder-PTV
Volume [cm3] - 151.0 ± 100.6 119.5 ± 93.5
Mean dose [Gy] < 45Gy 44.5 ± 12.3 35.5 ± 11.1
D2% [Gy]
< 80Gy 79.4 ± 1.2 72.6 ± 2.4
D67% [Gy]
Minimize 29.4 ± 17.2 23.7 ± 14.0
V30Gy [%]
Minimize 65.8 ± 20.5 57.5 ± 22.7
NTCP [%] < 5% 2.6 ± 4.0 0.1 ± 0.2
Femurs
Volume [cm3] - 373.3 ± 86.7
Mean dose [Gy] Minimise 19.4 ± 4.2
V45Gy [%]
Minimise 0.4 ± 1.0
D2% [Gy]
< 47Gy 36.7 ± 5.4
Penile Bulb
Volume [cm3] - 3.3 ± 1.2
Mean dose [Gy] < 30Gy 28.5 ± 17.2
D2% [Gy]
- 53.1 ± 23.7
Healthy 
Tissue
Volume [cm3] - 29054.2 ± 
7186.1
Mean dose [Gy] Minimise 5.1 ± 1.0
V10Gy [%]
Minimise 16.7 ± 3.2
V20Gy [%]
Minimise 9.3 ± 2.3
V30Gy [%]
Minimise 4.4 ± 1.2
DoseIntegral 
[105 Gy cm3]
Minimise 1.45 ± 0.32.6
Table 5: Clinical results at the end of radiotherapy.
Duration of RT [days] Mean ± SD [range] 58 ± 4 [52-66]
PSA pre-RT [μg/l] Median ± MAD 
[range]
6.7 ± 3.6 [0.1, 26.0]
PSA post-RT [μg/l] Median ± MAD 
[range]
0.4 ± 0.4 [0.0, 6.8]










Erectile function Yes 14/41 (34%)
Yes/No 4/41 (10%)
No 23/41 (56%)
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